Literature DB >> 10468180

Severe oral ulcerations induced by alendronate.

N Demerjian1, G Bolla, A Spreux.   

Abstract

The authors report the case of a 54-year-old man suffering from steroid-induced osteoporosis, who presented with severe oral ulcerations due to sucking alendronate tablets instead of swallowing them. The misuse of alendronate in this case, underlies the risk of direct mucosal injury with this drug.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10468180     DOI: 10.1007/s100670050116

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  10 in total

1.  A rare complication with a single dose of alendronate.

Authors:  Srinivasa Munigoti; Ricky Frazer; Alan Rees; Guy Blackshaw; Gareth Thomas; Aled Roberts
Journal:  BMJ Case Rep       Date:  2010-09-20

Review 2.  Alendronate: an update of its use in osteoporosis.

Authors:  M Sharpe; S Noble; C M Spencer
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  [Chronic mouth ulcer due to inadequate ingestion of alendronate].

Authors:  Francisco Cardona Tortajada; Esther Sainz Gómez; Jorge Figuerido Garmendia; Ana Lirón de Robles Adsuar
Journal:  Aten Primaria       Date:  2008-08       Impact factor: 1.137

Review 4.  Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease.

Authors:  Peter K Wong; Gelsomina L Borromeo; John D Wark
Journal:  Rheumatol Int       Date:  2013-05-08       Impact factor: 2.631

5.  Adsorption on apatitic calcium phosphates for drug delivery: interaction with bisphosphonate molecules.

Authors:  P Pascaud; F Errassifi; F Brouillet; S Sarda; A Barroug; A Legrouri; C Rey
Journal:  J Mater Sci Mater Med       Date:  2014-05-01       Impact factor: 3.896

6.  Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients.

Authors:  Arno Wutzl; Gabriela Eisenmenger; Martha Hoffmann; Christian Czerny; Doris Moser; Peter Pietschmann; Rolf Ewers; Arnulf Baumann
Journal:  Wien Klin Wochenschr       Date:  2006-08       Impact factor: 1.704

Review 7.  Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review.

Authors:  Raheem B Kherani; Alexandra Papaioannou; Jonathan D Adachi
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 8.  Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass.

Authors:  Ronald C Hamdy
Journal:  Drug Des Devel Ther       Date:  2010-11-18       Impact factor: 4.162

9.  Multiple systemic diseases complicated by bisphosphonate osteonecrosis: a case report.

Authors:  Fabrizio Carini; Lorena Barbano; Vito Saggese; Dario Monai; Gianluca Porcaro
Journal:  Ann Stomatol (Roma)       Date:  2012-11-14

10.  Evolution of bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma and Waldenstrom's macroglobulinemia: a retrospective multicentric study.

Authors:  A Andriani; M T Petrucci; T Caravita; M Montanaro; N Villivà; A Levi; A Siniscalchi; V Bongarzoni; F Pisani; M De Muro; U Coppetelli; G Avvisati; A Zullo; A Agrillo; D Gaglioti
Journal:  Blood Cancer J       Date:  2012-03-23       Impact factor: 11.037

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.